Abstract
背景与目的表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitors, EGFR-TKIs)在EGFR突变型肺腺癌人群中能显著提高生存,从而改变了晚期肺癌的治疗模式,但并不是所有EGFR敏感突变者均能从EGFR-TKIs治疗中获益。本研究欲通过外周血肿瘤标志物的检测对突变型肺腺癌患者的靶向治疗进行预测及指导。方法回顾性分析2009年6月-2014年6月于北京大学肿瘤医院胸部肿瘤内一科一线接受EGFR-TKIs治疗的EGFR突变型Ⅲb期-Ⅳ期肺腺癌患者的临床资料,分析其基线肿瘤标志物与EGFR-TKIs疗效及生存的关系。结果总体人群客观有效率(objective response rate, ORR)52.8%,疾病控制率(disease control rate, DCR)89.3%。基线癌胚抗原(carcino-embryonic antigen, CEA)水平升高者对EGFR-TKIs疗效更佳(ORR 61.3% vs 35.9%, DCR 95.2% vs 74.4%, P < 0.001),治疗1个月后CEA、细胞角蛋白19片段(cytokeratin 19 fragments, CYFRA21-1)以及CA125水平下降者有效率更高(ORR分别是61.5% vs 25%,P=0.002;58.5% vs 37.5%,P=0.004;61.8% vs 20%,P=0.027)。生存分析中,基线CEA水平正常者较高水平者无进展生存期(progression-free survival, PFS)明显缩短(中位PFS 5.9个月vs 9.8个月,P=0.027),而基线CYFRA21-1、CA125水平升高者PFS明显缩短(中位PFS 9.0个月vs 11.4个月,P=0.029;9.0个月vs 11.5个月,P=0.023)。多因素分析显示,美国东部肿瘤协作组(Eastern Cooperative Oncology Group, ECOG)评分0-1分、基线CYFRA21-1正常水平、治疗1月后CEA下降阳性患者PFS更长。总生存期(overall survival, OS)与CYFRA21-1、CA125升高有关(中位OS分别为25.1个月vs 52.5个月,P=0.003;22.7个月vs 55.0个月,P < 0.001),而多因素分析中总生存与CEA下降有关(P=0.046)。结论治疗前高水平CEA以及治疗后CEA下降可以预测晚期肺腺癌患者一线接受EGFR-TKIs的疗效,而治疗前高水平CYFRA21-1以及CA125则预示着生存期缩短。
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.